

3. Final financial report and performance report, no later than 90 days after the end of the project period; and

**Note:** Send all reports to the Grants Management Specialist identified in section "I. Where Can I Get More Information."

If funded, CDC staff will visit your organization to learn about your activities. When asking for the continuation awards, you must again show CDC that you still meet the requirements stated under "B. Who Can Apply?"

**Note:** Successful applicants may be contacted by the National Prevention Information Network (NPIN) to obtain information on their program resources. Your resources may be used in referrals and resource directories. If selected for funding, three copies of all educational materials and resources developed under this grant should be sent to NPIN for inclusion in their databases.

If you develop HIV prevention materials using CDC funds, you must first check with NPIN to find out if the same kind of materials have already been developed.

NPIN also makes available information and technical assistance services for use in program planning and evaluation. They can be contacted at the numbers and Internet site given above.

NPIN makes available materials on HIV, STD, and TB to the general public through its Internet site ([www.cdcpin.org](http://www.cdcpin.org)), its 1-800 number (1-800-458-5231; TTY users: 1-800-243-7012), and fax number (1-888-282-7681).

#### *Human Subjects Guidelines*

If you are conducting a research project that involves human subjects, you must ensure that your application includes or addresses the following:

1. Requirements of Title 45 CFR Part 46 for the protection of human subjects? (Not scored; however, an application can be disapproved if the research risks are sufficiently serious and protection against risks is so inadequate as to make the entire application unacceptable.)

2. Requirements of CDC Policy regarding the inclusion of women, ethnic, and racial groups in the proposed research.

This includes:

a. The proposed plan for the inclusion of both sexes and racial and ethnic minority populations for appropriate representation.

b. The proposed justification when representation is limited or absent.

c. A statement as to whether the design of the study is adequate to measure differences when warranted.

d. A statement as to whether the plans for recruitment and outreach for study

participants include the process of establishing partnerships with community(ies) and recognition of mutual benefits.

**Note:** Projects that involve the collection of information from 10 or more individuals and funded by cooperative agreement will be subject to review and approval by the Office of Management and Budget (OMB) under the Paperwork Reduction Act.

#### **I. Authority and Catalog of Federal Domestic Assistance Number**

This program is authorized under section 301(a) and 317 of the Public Health Service Act, [42 U.S.C. section 241(a) and 247(b)], as amended. The Catalog of Federal Domestic Assistance number is 93.939.

#### **J. Where To Obtain Additional Information**

CDC strongly suggests that you supplement this program announcement as it appears in the **Federal Register**, with a copy of the program announcement that is in an easy-to-use format. This easy-to-read version can be found on the CDC home page Internet address <http://www.cdc.gov>. Click on "Funding" then "Grants and Cooperative Agreements."

To request a hard copy of the application, call 1-888-GRANTS4(1-888-472-6874). You will be asked to leave your name and address and will be instructed to identify the Program Announcement number you want.

If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from: David A. Wilson, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341-4146, Telephone number: 770-488-2700, E-mail address: [DAWilson@cdc.gov](mailto:DAWilson@cdc.gov).

For program technical assistance, contact: Bill Comeaux, Project Officer, Prevention Program Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, MS-E58, Atlanta, GA 30333, Telephone number: 404-639-0968, E-mail address: [wcomeaux@cdc.gov](mailto:wcomeaux@cdc.gov).

Dated: June 15, 2001.

**John L. Williams,**

*Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 01-15595 Filed 6-20-01; 8:45 am]

**BILLING CODE 4163-18-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Centers for Disease Control and Prevention**

[Announcement Number 01094]

#### **Professional Education on Prostate Cancer: Primary Health Care Providers; Notice of Availability of Funds; Amendment**

A notice announcing the availability of Fiscal Year 2001 funds to fund a competing cooperative agreement program for private and public nonprofit medical organizations or associations which was published in the **Federal Register** on May 22, 2001 (Vol. 66, No. 99, Pages 28174-28177).

The notice is amended as follows:

On page 28176, Second Column, under Section F. Submission and Deadline, the submission due date should read on or before June 29, 2001.

Dated: June 15, 2001.

**Sandra R. Manning,**

*Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 01-15596 Filed 6-20-01; 8:45 am]

**BILLING CODE 4163-18-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Centers for Disease Control and Prevention**

#### **Cooperative Research and Development Agreement (CRADA)**

**AGENCY:** Centers for Disease Control and Prevention (CDC), HHS.

**ACTION:** Notice.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC) is seeking a CRADA partner for collaboration to examine the use of anti-substance P antibodies and/or anti-substance P F(ab)'<sub>2</sub> antibody fragments to prevent and/or treat an inflammatory response mediated by substance P associated with respiratory viral infection (particularly respiratory syncytial virus [RSV]). Anti-substance P antibody treatment would be used in combination with agents for anti-viral treatment (e.g., Ribavirin, palivizumab, and RSV fusion inhibitors) to ameliorate substance P-mediated inflammation and disease pathogenesis.

Because CRADAs are designed to facilitate the development of scientific and technologic knowledge into useful, marketable products, a great deal of freedom is given to Federal agencies in